Our Mission

We're creating the Primal Light Platform™ category:

Precision Phototherapy for Natural Synthesis.

Our mission is to give people the biological optimization their bodies evolved to receive, but with modern safety and precision.

WHY WE EXIST

The problem was clear: Vitamin D supplements fail 1 in 4 people due to absorption issues. Natural sunlight is dangerous and impossible to dose correctly. Generic UVB lamps have no safety controls and require manual calculations that most people get wrong.
 
We built Enyrgy to solve all three problems: precision-engineered UVB synthesis with third-party validated spectrum output, automatic MED-based safety protocols, and the complete Triple-Pathway Advantage (vitamin D + nitric oxide + serotonin) that supplements and isolated UVB can't deliver.

OUR SCIENTIFIC ADVISORY TEAM

Dr. Bruce Hollis has 40+ years at the forefront of vitamin D research with over 70,000 citations of his published work. He's a pioneer in UVB phototherapy and validates our dosing protocols.
 
Dr. William B. Grant has published 350+ peer-reviewed articles on vitamin D and health. He used NASA UVB data to establish links between sunlight exposure and disease prevention. His work provides the epidemiological foundation for our market education.
 
Dr. Samantha Kimball has over 20 years in vitamin D research and has published 100+ peer-reviewed papers. She designed our MED protocol and ensured our safety standards are medically sound.

PUBLISHED RESEARCH FOUNDATION

While Enyrgy Primal Light™ is a new technology platform, our approach is grounded in decades of published phototherapy research:

 

UVB-TRIGGERED VITAMIN D SYNTHESIS:

• Holick, M.F. (2007). "Vitamin D deficiency." New England Journal of Medicine, 357(3), 266-281.

• Webb, A.R., et al. (2017). "Influence of season and latitude on the cutaneous synthesis of vitamin D3." Journal of Clinical Endocrinology & Metabolism.

• Chel, V., et al. (2008). "Efficacy of different doses and time intervals of oral vitamin D supplementation with or without calcium in elderly nursing home residents." Osteoporosis International.

 

UVA-INDUCED NITRIC OXIDE RELEASE:

• Liu, D., et al. (2014). "UVA irradiation of human skin vasodilates arterial vasculature and lowers blood pressure independently of nitric oxide synthase." Journal of Investigative Dermatology, 134(7), 1839-1846.

• Feelisch, M., et al. (2010). "Is sunlight good for our heart?" European Heart Journal, 31(9), 1041-1045.

 

UVA-TRIGGERED SEROTONIN PRODUCTION:

• Gambichler, T., et al. (2002). "Plasma levels of opioid peptides after repeated exposure to ultraviolet radiation." British Journal of Dermatology, 147(6), 1207-1211.

• Kaur, M., et al. (2019). "Role of serotonin in seasonal affective disorder." European Review for Medical and Pharmacological Sciences.

 

NATURAL SYNTHESIS VS. ORAL SUPPLEMENTATION:

• Heaney, R.P., et al. (2011). "Letter to Veugelers, P.J. and Ekwaru, J.P.: A statistical error in the estimation of the recommended dietary allowance for vitamin D." Nutrients, 6(10), 4472-4475.

• Luxwolda, M.F., et al. (2012). "Traditionally living populations in East Africa have a mean serum 25-hydroxyvitamin D concentration of 115 nmol/l." British Journal of Nutrition, 108(9), 1557-1561.

VALIDATION & CLINICAL DATA

Third-Party Verified. Cohort Study Proven.

 

INDEPENDENT LABORATORY VALIDATION:

Third-party spectral analysis confirms our output: 90-95% UVB + 5-10% UVA. Not manufacturer claims. Independently measured and verified.

 

CLINICAL COHORT STUDY RESULTS:

Study Design: Internal 12-week observational study with N=5 participants (skin types II-IV). There was no control group. They were all healthy adults without contraindications. There was high compliance (average 5+ sessions/week).
 
Important Context: This is pilot data from a small cohort. We are transparent about limitations and are pursuing larger-scale peer-reviewed trials (target Q3 2026).

 

Summary Results:

• Average baseline vitamin D: 39.96 ng/mL (deficient to insufficient range)
• Average ending vitamin D: 84.2 ng/mL (optimal range)
• Average increase: +44.24 ng/mL (+111% increase)
• 100% of participants exceeded optimal range (60-80 ng/mL)
• Zero adverse events or burns reported
• Treatment frequency: Average 61.6 sessions over 12 weeks (5.1 sessions/week)

 

Individual Results:

• Participant 1 (M, Skin Type II): 38.4 → 86 ng/mL (+124% increase, 82 treatments)
• Participant 2 (M, Skin Type III): 34 → 88.4 ng/mL (+160% increase, 43 treatments)
• Participant 3 (M, Skin Type III): 37 → 78 ng/mL (+111% increase, 51 treatments)
• Participant 4 (M, Skin Type IV): 47 → 88.7 ng/mL (+89% increase, 85 treatments)
• Participant 5 (F, Skin Type III): 43.4 → 79.9 ng/mL (+84% increase, 47 treatments)

 

Study Limitations:

• Small sample size (N=5)
• No control group (observational study)
• Self-reported energy/mood metrics (not included in data above)
• Participants were highly compliant (average 5+ in office sessions/week)
• All participants were healthy adults without contraindications

 

Transparency Commitment:

Full study protocol, raw data, and measurement methodology available upon request.